EGFR and neoplasm: Genetic inhibition of cytonemes by downregulation of five genes that were shown previously to be essential in cytoneme-mediated signaling, reduced tumor growth, and we describe genetic conditions that suppress lethality by as much as 60% in the EGFR-Pcn tumor and by as much as 30% in the RETMEN2 tumor.